Archive for January, 2011
Hopes for Rivaroxaban Are Dashed (JNJ, $65.00)
Investment Opinion The FDA problems encountered with rivaroxaban are a significant, but not crushing negative for the investment thesis of Johnson & Johnson (JNJ). I would still be buyer of the stock. This is a very large company not overly dependent on any one current or future product and still has an excellent new drug […]